It is the cache of ${baseHref}. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

Safety, efficacy and patient acceptability of the contraceptive and no
skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

14804

Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS



Review

(6586) Total Article Views


Authors: Paula H Bednarek, Jeffrey T Jensen

Published Date May 2009 Volume 2009:1 Pages 45 - 58
DOI: http://dx.doi.org/10.2147/IJWH.S4350

Paula H Bednarek, Jeffrey T Jensen

Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR, USA

Abstract: Intrauterine devices (IUDs) provide highly effective, long-term, safe, reversible contraception, and are the most widely used reversible contraceptive method worldwide. The levonorgestrel-releasing intrauterine system (LNG-IUS) is a T-shaped IUD with a steroid reservoir containing 52 mg of levonorgestrel that is released at an initial rate of 20 µg daily. It is highly effective, with a typical-use first year pregnancy rate of 0.1% – similar to surgical tubal occlusion. It is approved for 5 years of contraceptive use, and there is evidence that it can be effective for up to 7 years of continuous use. After removal, there is rapid return to fertility, with 1-year life-table pregnancy rates of 89 per 100 for women less than 30 years of age. Most users experience a dramatic reduction in menstrual bleeding, and about 15% to 20% of women become amenorrheic 1 year after insertion. The device’s strong local effects on the endometrium benefit women with various benign gynecological conditions such as menorrhagia, dysmenorrhea, leiomyomata, adenomyosis, and endometriosis. There is also evidence to support its role in endometrial protection during postmenopausal estrogen replacement therapy, and in the treatment of endometrial hyperplasia.

Keywords: levonorgestrel intrauterine system, LNG-IUS, intrauterine device, IUD, IUS




Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter

 

Other articles by Dr Jeffrey Jensen


Readers of this article also read:

  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, University of Texas Health Science Center, San Antonio.